USP to Provide Free Access to Quality Standards for AACP Students
The US Pharmacopeial Convention is partnering with the American Association of Colleges of Pharmacy to provide students with free access to quality standards.
The US Pharmacopeial Convention (USP) announced at the American Association of Colleges of Pharmacy’s (AACP’s) 2019 Pharmacy Education annual meeting, held July 13–17 in Chicago, that it will be partnering with AACP, a national organization representing pharmacy education in the United States, to provide its students with free access to the quality standards in USP’s compendia. The USP Academic Connection program will offer AACP institutional members free access to USP publications, discounts on educational programming, and other benefits. USP publishes quality standards for medicines in the United States Pharmacopeia–National Formulary (USP–NF) and for food in the Foods Chemicals Codex (FCC).
"We're delighted to make our quality standards available to health sciences faculty and students across academia through AACP member schools. Our nearly 200 years of accumulated knowledge represented through our public quality standards will enable this program to strengthen curriculums and better prepare students for their role as health science practitioners," said Ronald T. Piervincenzi, PhD, USP CEO.
"The USP Academic Connection, with free access to the online USP–NF and FCC standards, fits well within AACP's efforts to explore the role of pharmacy and pharmacy education in today’s challenging healthcare landscape," said Lucinda Maine, PhD, RPh, AACP executive vice-president and CEO.
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
